Anti-Parkinson Drugs Market Report 2026
Download Free Sample Buy Now
Anti-Parkinson Drugs Market Global Report 2026 Market Report Infographic Image
Item added to cart!

Published : February 2026

Pages : 175

Format : PDF

Delivery Time : 2-3 Business Days

Report Price : $4490.00

Purchase This Report Download Sample PDF
Purchase This Report

Anti-Parkinson Drugs Market Report 2026

Global Outlook – By Drugs Class (Levodopa Or Carbidopa, Dopamine Receptor Agonists, Monoamine Oxidase Type B (MAO-B) Inhibitors, Catechol-O-Methyltransferase (COMT)-inhibitors, Anticholinergics, Other Drugs ), By Route of Administration (Oral, Injection, Transdermal ), By Distribution Channel (Hospital Pharmacies, Retailer Pharmacies, Online Pharmacies ) - Market Size, Trends, And Global Forecast 2025-2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Anti-Parkinson Drugs Market Overview

• Anti-Parkinson Drugs market size has reached to $10.96 billion in 2025

• Expected to grow to $14.28 billion in 2030 at a compound annual growth rate (CAGR) of 5.6%

• Growth Driver: Increasing Incidence Of Mental Health Disorders Driving Market Growth Due To Rising Need For Supportive Wellness Solutions

• Market Trend: Innovative Advancements In The Anti-Parkinson Drugs Market

• North America was the largest region in 2025 and Middle East is the fastest growing region.

What Is Covered Under Anti-Parkinson Drugs Market?

Anti-Parkinson drug is a term used to describe the medications that are mostly used to treat Parkinson's disease. They are not psychiatric medications, so they cannot legally be used to treat mental health issues. However, a doctor or psychiatrist may recommend one of these medications in addition to an antipsychotic to lessen some of the antipsychotic's negative effects.

The main class of anti-Parkinson drugs is levodopa/carbidopa, dopamine receptor agonists, monoamine oxidase type b (MAO-b) inhibitors, catechol-o-methyltransferase (COMT)-inhibitors, anticholinergics, and other drugs. Catechol-O-methyltransferase (COMT) inhibitors are a class of drugs used to treat Parkinson's disease symptoms in conjunction with carbidopa-levodopa therapy. The main types of fertility drugs are prescription fertility drugs and over-the-counter fertility drugs. The drugs are administered through oral, injection, and transdermal that are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

Anti-Parkinson Drugs Market Global Report 2026 Market Report bar graph

What Is The Anti-Parkinson Drugs Market Size and Share 2026?

The anti-parkinson drugs market size has grown steadily in recent years. It will grow from $10.96 billion in 2025 to $11.46 billion in 2026 at a compound annual growth rate (CAGR) of 4.6%. The growth in the historic period can be attributed to aging population growth, increased parkinson’s disease diagnosis, long-standing use of levodopa, improved neurological care, chronic disease management needs.

What Is The Anti-Parkinson Drugs Market Growth Forecast?

The anti-parkinson drugs market size is expected to see strong growth in the next few years. It will grow to $14.28 billion in 2030 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to rising neurodegenerative disorders, innovation in neuroprotective drugs, expansion of transdermal therapies, increased healthcare access, focus on quality of life improvement. Major trends in the forecast period include rising demand for dopaminergic therapies, growing use of extended-release formulations, increasing focus on symptom management, expansion of combination drug therapies, improved drug delivery technologies.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us

Global Anti-Parkinson Drugs Market Segmentation

1) By Drugs Class: Levodopa Or Carbidopa, Dopamine Receptor Agonists, Monoamine Oxidase Type B (MAO-B) Inhibitors, Catechol-O-Methyltransferase (COMT)-inhibitors, Anticholinergics, Other Drugs

2) By Route of Administration: Oral, Injection, Transdermal

3) By Distribution Channel: Hospital Pharmacies, Retailer Pharmacies, Online Pharmacies

Subsegments:

1) By Levodopa Or Carbidopa: Immediate-Release Levodopa Or Carbidopa, Extended-Release Levodopa Or Carbidopa

2) By Dopamine Receptor Agonists: Pramipexole, Ropinirole, Rotigotine

3) By Monoamine Oxidase Type B (MAO-B) Inhibitors: Selegiline, Rasagiline, Safinamide

4) By Catechol-O-Methyltransferase (COMT)-Inhibitors: Entacapone, Tolcapone

5) By Anticholinergics: Benztropine, Trihexyphenidyl

6) By Other Drugs: Amantadine, Apomorphine

What Is The Driver Of The Anti-Parkinson Drugs Market?

The increasing incidence of mental health disorders is expected to propel the growth of the mental wellness market going forward. The mental health disorders is a clinically substantial impairment in a person's cognition, emotional regulation, or conduct. The rising prevalence of mental disorders is due to increasing exposure to chronic stress and adverse life experiences that overwhelm individual coping mechanisms and trigger psychological dysfunction. The increasing incidence of mental disorders expands the anti-Parkinson drugs market as it aids in minimizing mental disorders and cures them. For instance, in October 2025, according to the Institute for Health Metrics and Evaluation, a US-based health research organization, 15% of the world’s population experienced mental disorders in 2023 and 17% of the total years lived with disability globally were attributed to mental disorders in the same year. Therefore, the high prevalence of mental disorder is driving the growth of the anti-Parkinson drugs industry.

Key Players In The Global Anti-Parkinson Drugs Market

Major companies operating in the anti-parkinson drugs market are GlaxoSmithKline plc, Pfizer Inc., Novartis AG, F. Hoffmann-La Roche AG, UCB S.A, Teva Pharmaceutical Industries Ltd., AbbVie Inc., Mylan NV, C.H. Boehringer Sohn AG & Co. KG, Orion Pharma Ltd., Sun Pharmaceutical Industries Ltd., Wockhardt Ltd., Reddy's Laboratories Ltd., Intas Pharmaceuticals Ltd., US WorldMeds LLC, Zydus Lifesciences Limited, Chemical Industrial & Pharmaceutical Laboratories Ltd., Strides Shasun Ltd., Upsher-Smith Laboratories LLC, H. Lundbeck A/S, Vertical Pharmaceuticals LLC, Zambon SPA, Valeant Pharmaceuticals International Inc., Neurocrine Biosciences Inc., Supernus Pharmaceuticals Inc.

Global Anti-Parkinson Drugs Market Trends and Insights

Major companies operating in the anti-Parkinson drugs market are focused on developing advanced therapeutic solutions such as motor fluctuations and dyskinesia to enhance symptom control and minimize side effects. Motor fluctuations and dyskinesia often complicate the treatment of Parkinson's disease, affecting patient well-being. For instance, in January 2024, AbbVie Inc., a US-based pharmaceutical company, launched PRODUODOPA. PRODUODOPA(foslevodopa/foscarbidopa) is the first subcutaneous 24-hour infusion therapy for advanced Parkinson's disease, specifically addressing severe motor fluctuations and dyskinesia when other treatments fail. It continuously delivers levodopa, potentially increasing 'on' time and improving symptom control.

Need data on a specific region in this market?
Request Regional Data

What Are Latest Mergers And Acquisitions In The Anti-Parkinson Drugs Market?

In October 2023, AbbVie Inc., a US-based pharmaceutical company, acquired Mitokinin for $110 million. With this acquisition, AbbVie Inc. aims to strengthen the neuroscience pipeline and provide a new treatment option for Parkinson patients. Mitokinin is a US-based biotechnology company that provides treatments for Parkinson disease (PD).

Regional Insights

North America was the largest region in the anti-Parkinson drugs market in 2025. Middle East is expected to be the fastest-growing region in the anti-parkinson drugs market during the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Anti-Parkinson Drugs Market?

The anti-parkinson drugs market consists of sales of catechol-O-methyl transferase [COMT] inhibitors, anticholinergic drugs, and amantadine. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Anti-Parkinson Drugs Market Report 2026?

The anti-parkinson drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the anti-parkinson drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Author : Abhilash Pyata

Anti-Parkinson Drugs Market Report Forecast Analysis

Report AttributeDetails
Market Size Value In 2026 $11.46 billion
Revenue Forecast In 2035 $14.28 billion
Growth Rate CAGR of 4.6% from 2026 to 2035
Base Year For Estimation 2025
Actual Estimates/Historical Data 2020-2025
Forecast Period 2026 - 2030 - 2035
Market Representation Revenue in USD Billion and CAGR from 2026 to 2035
Segments Covered Drugs Class, Route of Administration, Distribution Channel
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, ...
Key Companies Profiled GlaxoSmithKline plc, Pfizer Inc., Novartis AG, F. Hoffmann-La Roche AG, UCB S.A, Teva Pharmaceutical Industries Ltd., AbbVie Inc., Mylan NV, C.H. Boehringer Sohn AG & Co. KG, Orion Pharma Ltd., Sun Pharmaceutical Industries Ltd., Wockhardt Ltd., Reddy's
Customization ScopeRequest for Customization
Pricing And Purchase OptionsExplore Purchase Options

Table Of Contents

1. Executive Summary

1.1. Key Market Insights (2020-2035)

1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots

1.3. Major Factors Driving the Market

1.4. Top Three Trends Shaping the Market

2. Anti-Parkinson Drugs Market Characteristics

2.1. Market Definition & Scope

2.2. Market Segmentations

2.3. Overview of Key Products and Services

2.4. Global Anti-Parkinson Drugs Market Attractiveness Scoring And Analysis

2.4.1. Overview of Market Attractiveness Framework

2.4.2. Quantitative Scoring Methodology

2.4.3. Factor-Wise Evaluation

Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation

2.4.4. Market Attractiveness Scoring and Interpretation

2.4.5. Strategic Implications and Recommendations

3. Anti-Parkinson Drugs Market Supply Chain Analysis

3.1. Overview of the Supply Chain and Ecosystem

3.2. List Of Key Raw Materials, Resources & Suppliers

3.3. List Of Major Distributors and Channel Partners

3.4. List Of Major End Users

4. Global Anti-Parkinson Drugs Market Trends And Strategies

4.1. Key Technologies & Future Trends

4.1.1 Biotechnology, Genomics & Precision Medicine

4.1.2 Artificial Intelligence & Autonomous Intelligence

4.1.3 Digitalization, Cloud, Big Data & Cybersecurity

4.1.4 Industry 4.0 & Intelligent Manufacturing

4.1.5 Sustainability, Climate Tech & Circular Economy

4.2. Major Trends

4.2.1 Rising Demand For Dopaminergic Therapies

4.2.2 Growing Use Of Extended-Release Formulations

4.2.3 Increasing Focus On Symptom Management

4.2.4 Expansion Of Combination Drug Therapies

4.2.5 Improved Drug Delivery Technologies

5. Anti-Parkinson Drugs Market Analysis Of End Use Industries

5.1 Hospitals

5.2 Neurology Clinics

5.3 Specialty Care Centers

5.4 Retail Pharmacies

5.5 Long-Term Care Facilities

6. Anti-Parkinson Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Anti-Parkinson Drugs Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

7.1. Global Anti-Parkinson Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

7.2. Global Anti-Parkinson Drugs Market Size, Comparisons And Growth Rate Analysis

7.3. Global Anti-Parkinson Drugs Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)

7.4. Global Anti-Parkinson Drugs Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Anti-Parkinson Drugs Total Addressable Market (TAM) Analysis for the Market

8.1. Definition and Scope of Total Addressable Market (TAM)

8.2. Methodology and Assumptions

8.3. Global Total Addressable Market (TAM) Estimation

8.4. TAM vs. Current Market Size Analysis

8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Anti-Parkinson Drugs Market Segmentation

9.1. Global Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Levodopa Or Carbidopa, Dopamine Receptor Agonists, Monoamine Oxidase Type B (MAO-B) Inhibitors, Catechol-O-Methyltransferase (COMT)-inhibitors, Anticholinergics, Other Drugs

9.2. Global Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Oral, Injection, Transdermal

9.3. Global Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Hospital Pharmacies, Retailer Pharmacies, Online Pharmacies

9.4. Global Anti-Parkinson Drugs Market, Sub-Segmentation Of Levodopa Or Carbidopa, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Immediate-Release Levodopa Or Carbidopa, Extended-Release Levodopa Or Carbidopa

9.5. Global Anti-Parkinson Drugs Market, Sub-Segmentation Of Dopamine Receptor Agonists, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Pramipexole, Ropinirole, Rotigotine

9.6. Global Anti-Parkinson Drugs Market, Sub-Segmentation Of Monoamine Oxidase Type B (MAO-B) Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Selegiline, Rasagiline, Safinamide

9.7. Global Anti-Parkinson Drugs Market, Sub-Segmentation Of Catechol-O-Methyltransferase (COMT)-Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Entacapone, Tolcapone

9.8. Global Anti-Parkinson Drugs Market, Sub-Segmentation Of Anticholinergics, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Benztropine, Trihexyphenidyl

9.9. Global Anti-Parkinson Drugs Market, Sub-Segmentation Of Other Drugs, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Amantadine, Apomorphine

10. Anti-Parkinson Drugs Market Regional And Country Analysis

10.1. Global Anti-Parkinson Drugs Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

10.2. Global Anti-Parkinson Drugs Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Anti-Parkinson Drugs Market

11.1. Asia-Pacific Anti-Parkinson Drugs Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

11.2. Asia-Pacific Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Anti-Parkinson Drugs Market

12.1. China Anti-Parkinson Drugs Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

12.2. China Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Anti-Parkinson Drugs Market

13.1. India Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Anti-Parkinson Drugs Market

14.1. Japan Anti-Parkinson Drugs Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

14.2. Japan Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Anti-Parkinson Drugs Market

15.1. Australia Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Anti-Parkinson Drugs Market

16.1. Indonesia Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Anti-Parkinson Drugs Market

17.1. South Korea Anti-Parkinson Drugs Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

17.2. South Korea Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Anti-Parkinson Drugs Market

18.1. Taiwan Anti-Parkinson Drugs Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

18.2. Taiwan Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Anti-Parkinson Drugs Market

19.1. South East Asia Anti-Parkinson Drugs Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

19.2. South East Asia Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Anti-Parkinson Drugs Market

20.1. Western Europe Anti-Parkinson Drugs Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

20.2. Western Europe Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Anti-Parkinson Drugs Market

21.1. UK Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Anti-Parkinson Drugs Market

22.1. Germany Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Anti-Parkinson Drugs Market

23.1. France Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Anti-Parkinson Drugs Market

24.1. Italy Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Anti-Parkinson Drugs Market

25.1. Spain Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Anti-Parkinson Drugs Market

26.1. Eastern Europe Anti-Parkinson Drugs Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

26.2. Eastern Europe Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Anti-Parkinson Drugs Market

27.1. Russia Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Anti-Parkinson Drugs Market

28.1. North America Anti-Parkinson Drugs Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

28.2. North America Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Anti-Parkinson Drugs Market

29.1. USA Anti-Parkinson Drugs Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

29.2. USA Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Anti-Parkinson Drugs Market

30.1. Canada Anti-Parkinson Drugs Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

30.2. Canada Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Anti-Parkinson Drugs Market

31.1. South America Anti-Parkinson Drugs Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

31.2. South America Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Anti-Parkinson Drugs Market

32.1. Brazil Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Anti-Parkinson Drugs Market

33.1. Middle East Anti-Parkinson Drugs Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

33.2. Middle East Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Anti-Parkinson Drugs Market

34.1. Africa Anti-Parkinson Drugs Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

34.2. Africa Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Anti-Parkinson Drugs Market Regulatory and Investment Landscape

36. Anti-Parkinson Drugs Market Competitive Landscape And Company Profiles

36.1. Anti-Parkinson Drugs Market Competitive Landscape And Market Share 2024

36.1.1. Top 10 Companies (Ranked by revenue/share)

36.2. Anti-Parkinson Drugs Market - Company Scoring Matrix

36.2.1. Market Revenues

36.2.2. Product Innovation Score

36.2.3. Brand Recognition

36.3. Anti-Parkinson Drugs Market Company Profiles

36.3.1. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

36.3.2. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

36.3.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

36.3.4. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis

36.3.5. UCB S.A Overview, Products and Services, Strategy and Financial Analysis

37. Anti-Parkinson Drugs Market Other Major And Innovative Companies

Teva Pharmaceutical Industries Ltd., AbbVie Inc., Mylan NV, C.H. Boehringer Sohn AG & Co. KG, Orion Pharma Ltd., Sun Pharmaceutical Industries Ltd., Wockhardt Ltd., Reddy's Laboratories Ltd., Intas Pharmaceuticals Ltd., US WorldMeds LLC, Zydus Lifesciences Limited, Chemical Industrial & Pharmaceutical Laboratories Ltd., Strides Shasun Ltd., Upsher-Smith Laboratories LLC, H. Lundbeck A/S

38. Global Anti-Parkinson Drugs Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Anti-Parkinson Drugs Market

40. Anti-Parkinson Drugs Market High Potential Countries, Segments and Strategies

40.1 Anti-Parkinson Drugs Market In 2030 - Countries Offering Most New Opportunities

40.2 Anti-Parkinson Drugs Market In 2030 - Segments Offering Most New Opportunities

40.3 Anti-Parkinson Drugs Market In 2030 - Growth Strategies

40.3.1 Market Trend Based Strategies

40.3.2 Competitor Strategies

41. Appendix

41.1. Abbreviations

41.2. Currencies

41.3. Historic And Forecast Inflation Rates

41.4. Research Inquiries

41.5. The Business Research Company

41.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Anti-Parkinson Drugs Market, Overview Of Key Products - Product Examples
  • Table 2: Global Anti-Parkinson Drugs Market Attractiveness, Factor-Wise Evaluation
  • Table 3: Global Anti-Parkinson Drugs Market, Supply Chain Analysis
  • Table 4: Global Anti-Parkinson Drugs Market, Major Raw Material Providers
  • Table 5: Global Anti-Parkinson Drugs Market, Major Resource Providers
  • Table 6: Global Anti-Parkinson Drugs Market, Major Manufacturers (Suppliers)
  • Table 7: Global Anti-Parkinson Drugs Market, Major Distributors And Channel Partners
  • Table 8: Global Anti-Parkinson Drugs Market, Key Technologies & Future Trends
  • Table 9: Global Anti-Parkinson Drugs Market, Major Trends
  • Table 10: Global Anti-Parkinson Drugs Market, Major End Users
  • Table 11: Global Anti-Parkinson Drugs Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis
  • Table 12: Global Anti-Parkinson Drugs Historic Market Growth, 2020-2025, $ Billion
  • Table 13: Global Anti-Parkinson Drugs Forecast Market Growth, 2025-2030F, 2035F, $ Billion
  • Table 14: Global Anti-Parkinson Drugs Market - TAM, US$ Billion, 2025
  • Table 15: Global Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 16: Global Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 17: Global Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 18: Global Anti-Parkinson Drugs Market, Sub-Segmentation Of Levodopa Or Carbidopa, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 19: Global Anti-Parkinson Drugs Market, Sub-Segmentation Of Dopamine Receptor Agonists, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 20: Global Anti-Parkinson Drugs Market, Sub-Segmentation Of Monoamine Oxidase Type B (MAO-B) Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 21: Global Anti-Parkinson Drugs Market, Sub-Segmentation Of Catechol-O-Methyltransferase (COMT)-Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 22: Global Anti-Parkinson Drugs Market, Sub-Segmentation Of Anticholinergics, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 23: Global Anti-Parkinson Drugs Market, Sub-Segmentation Of Other Drugs, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 24: Global Anti-Parkinson Drugs Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 25: Global Anti-Parkinson Drugs Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 26: Asia-Pacific, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 27: Asia-Pacific, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 28: Asia-Pacific, Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 29: China, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 30: China, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 31: China, Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 32: India, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 33: India, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 34: India, Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 35: Japan, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 36: Japan, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 37: Japan, Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 38: Australia, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 39: Australia, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 40: Australia, Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 41: Indonesia, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 42: Indonesia, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 43: Indonesia, Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 44: South Korea, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 45: South Korea, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 46: South Korea, Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 47: Taiwan, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 48: Taiwan, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 49: Taiwan, Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 50: South East Asia, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 51: South East Asia, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 52: South East Asia, Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 53: Western Europe, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 54: Western Europe, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 55: Western Europe, Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 56: UK, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 57: UK, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 58: UK, Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 59: Germany, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 60: Germany, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 61: Germany, Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 62: France, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 63: France, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 64: France, Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 65: Italy, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 66: Italy, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 67: Italy, Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 68: Spain, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 69: Spain, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 70: Spain, Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 71: Eastern Europe, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 72: Eastern Europe, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 73: Eastern Europe, Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 74: Russia, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 75: Russia, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 76: Russia, Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 77: North America, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 78: North America, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 79: North America, Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 80: USA, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 81: USA, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 82: USA, Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 83: Canada, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 84: Canada, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 85: Canada, Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 86: South America, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 87: South America, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 88: South America, Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 89: Brazil, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 90: Brazil, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 91: Brazil, Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 92: Middle East, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 93: Middle East, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 94: Middle East, Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 95: Africa, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 96: Africa, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 97: Africa, Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 98: Global Anti-Parkinson Drugs Key Competitor Estimated Market Shares, 2024, Percentage (%)
  • Table 99: Global Anti-Parkinson Drugs Market - Company Scoring Matrix
  • Table 100: GlaxoSmithKline plc Financial Performance
  • Table 101: Pfizer Inc. Financial Performance
  • Table 102: Novartis AG Financial Performance
  • Table 103: F. Hoffmann-La Roche AG Financial Performance
  • Table 104: UCB S.A Financial Performance
  • Table 105: Global Anti-Parkinson Drugs Market, Competitive Benchmarking (In USD Billions)
  • Table 106: Global Anti-Parkinson Drugs Market, Competitive Dashboard
  • Table 107: Global Anti-Parkinson Drugs Market Size Gain ($ Billion), 2025 – 2030 By Country
  • Table 108: Global, Anti-Parkinson Drugs Market Size Gain ($ Billion), Segmentation By Drugs Class, 2025 – 2030
  • Table 109: Global, Anti-Parkinson Drugs Market Size Gain ($ Billion), Segmentation By Route of Administration, 2025 – 2030
  • Table 110: Global, Anti-Parkinson Drugs Market Size Gain ($ Billion), Segmentation By Distribution Channel, 2025 – 2030

List Of Figures

    Figure 1: Global Anti-Parkinson Drugs Market, Overview Of Key Products - Product Examples
  • Figure 2: Global Anti-Parkinson Drugs Market Attractiveness, Factor-Wise Evaluation
  • Figure 3: Global Anti-Parkinson Drugs Market, Supply Chain Analysis
  • Figure 4: Global Anti-Parkinson Drugs Market, Major Raw Material Providers
  • Figure 5: Global Anti-Parkinson Drugs Market, Major Resource Providers
  • Figure 6: Global Anti-Parkinson Drugs Market, Major Manufacturers (Suppliers)
  • Figure 7: Global Anti-Parkinson Drugs Market, Major Distributors And Channel Partners
  • Figure 8: Global Anti-Parkinson Drugs Market, Key Technologies & Future Trends
  • Figure 9: Global Anti-Parkinson Drugs Market, Major Trends
  • Figure 10: Global Anti-Parkinson Drugs Market, Major End Users
  • Figure 11: Global Anti-Parkinson Drugs Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis
  • Figure 12: Global Anti-Parkinson Drugs Historic Market Growth, 2020-2025, $ Billion
  • Figure 13: Global Anti-Parkinson Drugs Forecast Market Growth, 2025-2030F, 2035F, $ Billion
  • Figure 14: Global Anti-Parkinson Drugs Market - TAM, US$ Billion, 2025
  • Figure 15: Global Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 16: Global Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 17: Global Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 18: Global Anti-Parkinson Drugs Market, Sub-Segmentation Of Levodopa Or Carbidopa, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 19: Global Anti-Parkinson Drugs Market, Sub-Segmentation Of Dopamine Receptor Agonists, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 20: Global Anti-Parkinson Drugs Market, Sub-Segmentation Of Monoamine Oxidase Type B (MAO-B) Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 21: Global Anti-Parkinson Drugs Market, Sub-Segmentation Of Catechol-O-Methyltransferase (COMT)-Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 22: Global Anti-Parkinson Drugs Market, Sub-Segmentation Of Anticholinergics, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 23: Global Anti-Parkinson Drugs Market, Sub-Segmentation Of Other Drugs, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 24: Global Anti-Parkinson Drugs Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 25: Global Anti-Parkinson Drugs Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 26: Asia-Pacific, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 27: Asia-Pacific, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 28: Asia-Pacific, Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 29: China, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 30: China, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 31: China, Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 32: India, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 33: India, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 34: India, Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 35: Japan, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 36: Japan, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 37: Japan, Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 38: Australia, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 39: Australia, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 40: Australia, Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 41: Indonesia, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 42: Indonesia, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 43: Indonesia, Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 44: South Korea, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 45: South Korea, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 46: South Korea, Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 47: Taiwan, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 48: Taiwan, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 49: Taiwan, Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 50: South East Asia, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 51: South East Asia, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 52: South East Asia, Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 53: Western Europe, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 54: Western Europe, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 55: Western Europe, Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 56: UK, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 57: UK, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 58: UK, Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 59: Germany, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 60: Germany, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 61: Germany, Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 62: France, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 63: France, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 64: France, Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 65: Italy, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 66: Italy, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 67: Italy, Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 68: Spain, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 69: Spain, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 70: Spain, Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 71: Eastern Europe, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 72: Eastern Europe, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 73: Eastern Europe, Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 74: Russia, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 75: Russia, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 76: Russia, Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 77: North America, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 78: North America, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 79: North America, Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 80: USA, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 81: USA, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 82: USA, Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 83: Canada, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 84: Canada, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 85: Canada, Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 86: South America, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 87: South America, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 88: South America, Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 89: Brazil, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 90: Brazil, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 91: Brazil, Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 92: Middle East, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 93: Middle East, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 94: Middle East, Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 95: Africa, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 96: Africa, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 97: Africa, Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 98: Global Anti-Parkinson Drugs Key Competitor Estimated Market Shares, 2024, Percentage (%)
  • Figure 99: Global Anti-Parkinson Drugs Market - Company Scoring Matrix
  • Figure 100: GlaxoSmithKline plc Financial Performance
  • Figure 101: Pfizer Inc. Financial Performance
  • Figure 102: Novartis AG Financial Performance
  • Figure 103: F. Hoffmann-La Roche AG Financial Performance
  • Figure 104: UCB S.A Financial Performance
  • Figure 105: Global Anti-Parkinson Drugs Market, Competitive Benchmarking (In USD Billions)
  • Figure 106: Global Anti-Parkinson Drugs Market, Competitive Dashboard
  • Figure 107: Global Anti-Parkinson Drugs Market Size Gain ($ Billion), 2025 – 2030 By Country
  • Figure 108: Global, Anti-Parkinson Drugs Market Size Gain ($ Billion), Segmentation By Drugs Class, 2025 – 2030
  • Figure 109: Global, Anti-Parkinson Drugs Market Size Gain ($ Billion), Segmentation By Route of Administration, 2025 – 2030
  • Figure 110: Global, Anti-Parkinson Drugs Market Size Gain ($ Billion), Segmentation By Distribution Channel, 2025 – 2030

2025 Bruton's Tyrosine Kinase (BTK) Inhibitor Market Outlook: Opportunities, Growth Trends, and Strategic Analysis

Read More About 2025 Bruton's Tyrosine Kinase (BTK) Inhibitor Market Outlook: Opportunities, Growth Trends, and Strategic Analysis

Future Projections: Calcitonin Gene-Related Peptide Receptor Antagonist Market to Reach $3.48 Billion by 2029 at 11% CAGR

Read More About Future Projections: Calcitonin Gene-Related Peptide Receptor Antagonist Market to Reach $3.48 Billion by 2029 at 11% CAGR

Comprehensive Forecast: Complementary And Alternative Medicine For Anti-Aging And Longevity Market Share, Growth, and Opportunities Through 2029

Read More About Comprehensive Forecast: Complementary And Alternative Medicine For Anti-Aging And Longevity Market Share, Growth, and Opportunities Through 2029

Global Compounding Chemotherapy Market Landscape: Trends and Market Share to 2029

Read More About Global Compounding Chemotherapy Market Landscape: Trends and Market Share to 2029

A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

Read More About A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

A 2025 market overview covering growth forecasts, treatment landscape, and key stakeholders in the isovaleric acidemia treatment market.

Read More About A 2025 market overview covering growth forecasts, treatment landscape, and key stakeholders in the isovaleric acidemia treatment market.

A dynamic 2025 report outlining growth drivers, pipeline innovations, and key markets in liver cancer therapeutics.

Read More About A dynamic 2025 report outlining growth drivers, pipeline innovations, and key markets in liver cancer therapeutics.

A 2025 analysis tracking API pricing, competitive landscape, and growth strategies in the losartan potassium active pharmaceutical ingredient market.

Read More About A 2025 analysis tracking API pricing, competitive landscape, and growth strategies in the losartan potassium active pharmaceutical ingredient market.

Central Nervous System Drugs Global Market Report 2022 – By Type (Analgesics, Anti-Parkinson Drugs, Anesthetics, Anti-Epileptics), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores), By Route O...

Cholinergic Drugs Market Report 2026 - Global Outlook – By Type (Powder, Tablet, Capsule), By Drug Type (Muscarinic Agonists, Nicotinic Agonists, Acetylcholinesterase Inhibitors), By Indication (Alzheimer's Disease, Myas...

Anti-Thyroid Drugs Market Report 2026 - Global Outlook – By Drug Type (Thionamides (Inhibition Of Hormone Synthesis), Iodides (Inhibition Of Hormone Release)), By Route of Administration (Oral, Intravenous, Other Route O...

Antiparasitic Drugs Market Report 2026 - Global Outlook – By Product Type (Anthelmintics, Antiprotozoals, Ectoparasiticide, Other Products), By Treatment (Avermectins, Bezimidazoles, Pyrimidines, Imidazolesthiazoles), By...

Anti-Parkinson Drugs Market Report 2026 - Global Outlook – By Drugs Class (Levodopa Or Carbidopa, Dopamine Receptor Agonists, Monoamine Oxidase Type B (MAO-B) Inhibitors, Catechol-O-Methyltransferase (COMT)-inhibitors, A...

Neurological Disorder Drugs Market Report 2026 - Global Outlook – By Drug Class (Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, Antiepileptic, Antipsychotic And Antidepressant, Other Drugs C...

Anticholinergic Drugs Market Report 2026 - Global Outlook – By Type (Synthetic Compounds, Natural, Semi-Synthetic Compounds), By Route Of Administration (Parental, Oral, Topical), By Application (Overactive Bladder, Park...

Antipsychotic Drugs Market Report 2026 - Global Outlook – By Therapeutic Class (First Generation, Second Generation, Third Generation), By Disease (Schizophrenia, Bipolar Disorder, Unipolar Depression, Dementia, Other Di...

Frequently Asked Questions

The Anti-Parkinson Drugs market was valued at $10.96 billion in 2025, increased to $11.46 billion in 2026, and is projected to reach $14.28 billion by 2030. request a sample here

The global Anti-Parkinson Drugs market is expected to grow at a CAGR of 5.6% from 2026 to 2035 to reach $14.28 billion by 2035. request a sample here

Some Key Players in the Anti-Parkinson Drugs market Include, GlaxoSmithKline plc, Pfizer Inc., Novartis AG, F. Hoffmann-La Roche AG, UCB S.A, Teva Pharmaceutical Industries Ltd., AbbVie Inc., Mylan NV, C.H. Boehringer Sohn AG & Co. KG, Orion Pharma Ltd., Sun Pharmaceutical Industries Ltd., Wockhardt Ltd., Reddy's Laboratories Ltd., Intas Pharmaceuticals Ltd., US WorldMeds LLC, Zydus Lifesciences Limited, Chemical Industrial & Pharmaceutical Laboratories Ltd., Strides Shasun Ltd., Upsher-Smith Laboratories LLC, H. Lundbeck A/S, Vertical Pharmaceuticals LLC, Zambon SPA, Valeant Pharmaceuticals International Inc., Neurocrine Biosciences Inc., Supernus Pharmaceuticals Inc. . request a sample here

Major trend in this market includes: Innovative Advancements In The Anti-Parkinson Drugs Market. For further insights on this market. request a sample here

North America was the largest region in the anti-Parkinson drugs market in 2025. Middle East is expected to be the fastest-growing region in the anti-parkinson drugs market during the forecast period. The regions covered in the anti-parkinson drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. request a sample here.

Major companies operating in the Anti-Parkinson Drugs Market Report 2026 market are Major companies operating in the anti-parkinson drugs market are GlaxoSmithKline plc, Pfizer Inc., Novartis AG, F. Hoffmann-La Roche AG, UCB S.A, Teva Pharmaceutical In request a sample here.

North America was the largest region in the anti-Parkinson drugs market in 2025. Middle East is expected to be the fastest-growing region in the anti-parkinson drugs market during the forecast period. The regions covered in the anti-parkinson drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. request a sample here.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us